Literature DB >> 22302674

Heat shock protein 27 and p16 immunohistochemistry in cervical intraepithelial neoplasia and squamous cell carcinoma.

Akiko Tozawa-Ono1, Ayako Yoshida, Noriyuki Yokomachi, Rumiko Handa, Hirotaka Koizumi, Kazushige Kiguchi, Bunpei Ishizuka, Nao Suzuki.   

Abstract

Heat shock protein 27 (hsp27) is expressed by squamous cell carcinoma of the uterine cervix. Results from an earlier study by our group indicted that hsp27 may be a diagnostic marker for cervical intraepithelial neoplasia (CIN) and carcinoma. p16 expression is known to be elevated in intraepithelial uterine cervical cancer and grades 2 and 3 lesions (CIN2, CIN3), but has also been reported to be negative in 5-20% of cervical cancer and CIN lesions. The aim of our study was to confirm immunohistochemically the expression of hsp27 and p16 in cervical lesions. Formalin-fixed, paraffin-embedded cervical tissue specimens obtained between 2002 and 2010 were investigated for hsp27 and p16 expression. Positive staining was detected for hsp27 in 63% of normal cervical tissues, 47% of CIN1 lesions, 75% of CIN2 lesions, 92% of CIN3 lesions, and 100% of squamous cell carcinomas (SCC); the corresponding rates for p16 positivity were 29, 47, 67, 92, and 75%, respectively. Positive staining for both hsp27 and p16 was observed in 6% of normal cervical tissues and in 19% of CIN1, 18% of CIN2, 85% of CIN3, and 75% of SCC specimens. Hsp27 or p16 positivity had a sensitivity of 95.6 or 84.7% and a specificity of 37.2 or 70.5%, respectively, for the identification of CIN3 or SCC lesions; when both hsp27 and p16 were assessed, both the sensitivity and specificity were improved. In conclusion, both hsp27 and p16 immunohistochemistry is a useful tool for the diagnosis of CIN3 lesions or cervical SCC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22302674     DOI: 10.1007/s13577-011-0040-1

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  18 in total

1.  Heat-shock proteins reverse the G2 arrest caused by HIV-1 viral protein R.

Authors:  Michael Bukrinsky; Yuqi Zhao
Journal:  DNA Cell Biol       Date:  2004-04       Impact factor: 3.311

Review 2.  [The pleiotropic activity of heat-shock proteins].

Authors:  Arleta Kaźmierczuk; Zofia M Kiliańska
Journal:  Postepy Hig Med Dosw (Online)       Date:  2009-10-27       Impact factor: 0.270

3.  p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia.

Authors:  Rüdiger Klaes; Axel Benner; Tibor Friedrich; Rüdiger Ridder; Simon Herrington; David Jenkins; Robert J Kurman; Dietmar Schmidt; Mark Stoler; Magnus von Knebel Doeberitz
Journal:  Am J Surg Pathol       Date:  2002-11       Impact factor: 6.394

4.  Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri.

Authors:  R Klaes; T Friedrich; D Spitkovsky; R Ridder; W Rudy; U Petry; G Dallenbach-Hellweg; D Schmidt; M von Knebel Doeberitz
Journal:  Int J Cancer       Date:  2001-04-15       Impact factor: 7.396

Review 5.  Heat-shock protein 27 (HSP27) and its role in female reproductive organs.

Authors:  O Devaja; R J King; A Papadopoulos; K S Raju
Journal:  Eur J Gynaecol Oncol       Date:  1997       Impact factor: 0.196

Review 6.  Heat shock proteins in breast cancer progression--a suitable case for treatment?

Authors:  Stuart K Calderwood
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

7.  Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis.

Authors:  H J Arts; H Hollema; W Lemstra; P H Willemse; E G De Vries; H H Kampinga; A G Van der Zee
Journal:  Int J Cancer       Date:  1999-06-21       Impact factor: 7.396

8.  p16(INK4A) expression is related to grade of cin and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome.

Authors:  M Branca; M Ciotti; D Santini; L Di Bonito; C Giorgi; A Benedetto; P Paba; C Favalli; S Costa; A Agarossi; M Alderisio; K Syrjänen
Journal:  Int J Gynecol Pathol       Date:  2004-10       Impact factor: 2.762

9.  Overexpression of p16 and p14ARF is associated with human papillomavirus infection in cervical squamous cell carcinoma and dysplasia.

Authors:  Takaaki Sano; Norihiro Masuda; Tetsunari Oyama; Takashi Nakajima
Journal:  Pathol Int       Date:  2002 May-Jun       Impact factor: 2.534

10.  Protein p 16INK4A expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of uterine cervix.

Authors:  Ruchi Gupta; Radhika Srinivasan; Raje Nijhawan; Vanita Suri; Radha Uppal
Journal:  Indian J Pathol Microbiol       Date:  2010 Jan-Mar       Impact factor: 0.740

View more
  5 in total

Review 1.  Revisiting the Old Data of Heat Shock Protein 27 Expression in Squamous Cell Carcinoma: Enigmatic HSP27, More Than Heat Shock.

Authors:  Shutao Zheng; Yan Liang; Lu Li; Yiyi Tan; Qing Liu; Tao Liu; Xiaomei Lu
Journal:  Cells       Date:  2022-05-17       Impact factor: 7.666

Review 2.  Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update.

Authors:  Daniel R Ciocca; Andre Patrick Arrigo; Stuart K Calderwood
Journal:  Arch Toxicol       Date:  2012-08-11       Impact factor: 5.153

3.  Ki-67 and P16 proteins in cervical cancer and precancerous lesions of young women and the diagnostic value for cervical cancer and precancerous lesions.

Authors:  Qin Shi; Ling Xu; Rong Yang; Yaping Meng; Lihua Qiu
Journal:  Oncol Lett       Date:  2019-06-03       Impact factor: 2.967

4.  p16 is superior to Stathmin-1 and HSP27 in identifying cervical dysplasia.

Authors:  Sofia Liou; Neshat Nilforoushan; Yuna Kang; Neda A Moatamed
Journal:  Diagn Pathol       Date:  2021-09-20       Impact factor: 2.644

Review 5.  Small Heat Shock Proteins in Cancers: Functions and Therapeutic Potential for Cancer Therapy.

Authors:  Jixian Xiong; Yuting Li; Xiangyu Tan; Li Fu
Journal:  Int J Mol Sci       Date:  2020-09-10       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.